The comparative study of the serum content of transforming growth factor (TGF-β<sub>1</sub>) on patients with locally advanced and metastatic prostate cancer
The serum concentrations of transforming growth factor (TGF)-β1, total and free prostate-specific antigen (PSA) were measured in patients with locally advanced and metastatic prostate cancer (PC) before special treatment and in the control group. Enzyme immunoassay in combination with conventional studies was used to examine patients with PC. In patients with metastatic PC, the serum level of TGF-β1 was significantly lower than that in healthy males (p = 0.003) and in patients with locally advanced PS (p = 0.002). Evidence was provided that there was a correlation between the serum concentration of TGF-β1 and the levels of total (r = 0.47; p = 0.04) and free (r = 0.48; p = 0.04) PSA in patients with locally advanced PC.